Rate Video

ESMO WCGIC 2020 | Regorafenib in refractory biliary tract cancer

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer FOLFOX Regorafenib

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, explores results from a Phase II study evaluating the use of regorafenib, a tyrosine kinase inhibitor, in refractory biliary tract cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

HIMALAYA: tremelimumab + durvalumab in unresectable HCC

Richard D. Kim • 27 Jan 2022

Regorafenib + nivolumab in MMR proficient advanced CRC

SWOG S1310: trametinib vs 5-FU/capecitabine in refractory advanced biliary cancer

Richard D. Kim • 2 Jul 2020

80mg regorafenib plus pembrolizumab for 1L HCC

Richard D. Kim • 10 Jun 2021

Related Videos

Novel developments in HCC treatment

COVID-19 & the management of cancer patients

Alberto F. Sobrero

HER-2 conversion: a phenomenon in trastuzumab resistance

The gut microbiome: role in causing and detecting colorectal cancer